The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive control merely drives patients underground. Regulation should protect safety, not ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...

Viccy Gibson paid just £70 for a month's supply of what she was told was semaglutide - the same ingredient used in ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

IF you’ve ever searched for weight loss tips online, you will know the deep rabbit hole that awaits. But now, social media ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

Lilly has the edge on Danish rival Novo to weather potential U.S. price cuts on its blockbuster obesity drug Zepbound, backed ...